Clostridium difficile: An Overview
|
|
- Darrell Flynn
- 6 years ago
- Views:
Transcription
1 Clostridium difficile: An Overview CDI Webinar July 11, 2017 PUBLIC HEALTH DIVISION Acute and Communicable Disease Prevention Section
2 Outline Background Microbiology Burden Pathogenesis Diagnostic testing Treatment Prevention Antimicrobial stewardship Practical approach to CDI prevention How is your facility dealing with CDI?
3 Background: Microbiology, Burden, Pathogenesis
4 C. difficile: Microbiology Gram-positive spore-forming obligate anaerobic rod-shaped bacterium 1935: part of flora of healthy infants; Bacillus difficilis 1-3% of heatlhy adults 70% of children < 12 months 1970s: C. difficile CDAD (CDI preferred) Toxins-producing strains cause C. difficile infection (CDI) Smits Nat Rev Dis Primers Apr 7; 2: doi: /nrdp
5 * Depending upon whether patient was discharged within previous 12 weeks Onset defined in NHSN by specimen collection date Time line for surveillance definitions of CDI Admission Discharge 2 d < 4 weeks 4-12 weeks > 12 weeks * Day 1 Day 4 HO CO- HCFA Time Indeterminate HO: Hospital (Healthcare)-Onset CO-HCFA: Community-Onset, Healthcare Facility- Associated CA: Community-Associated CA-CDI
6 C. difficile: Impact Estimated U.S. Burden of CDI, According to the Location of Stool Collection and Inpatient Health Care Exposure, ,000 CDI cases 1 293,000 healthcare-associated 107,000 hospital-onset 104,000 nursing home-onset 81,000 community-onset, healthcare-facility associated 160,000 community-associated 82% associated with outpatient healthcare exposure Overall, 94% of CDI cases related to healthcare 29,000 deaths $4.8 billion in excess healthcare costs 2 CO-HCA: Community onset healthcare-associated NHO: Nursing home onset HO: Hospital onset 1. Lessa et al. N Engl J Med 2015; 372(9): Dubberke et al. Clin Infect Dis 2012; 55:S88-92.
7 C. difficile: Impact C. difficile most commonly reported pathogen in 2011 multistate prevalence survey of healthcare-associated infections (HAI) % of 452 HAIs caused by CDI Rates of CDI per 1,000 discharges have risen through Magill et al. N Engl J Med 2014; 370: Steiner et al. HCUP Projections Report
8 Oregon C. difficile standardized infection ratios (SIR):
9 C. difficile : Transmission Fecal-oral route Contaminated hands of healthcare workers Contaminated environmental surfaces. Reservoir Human: colonized or infected persons Contaminated environment C. difficile spores can survive for up to 5 months on environmental surfaces.
10 CDI: Pathogenesis Step 1- Ingestion of spores transmitted from reservoirs Step 2- Germination into growing (vegetative) form Step 3 - Altered lower intestine flora (due to antimicrobial use) allows proliferation of C. difficile in colon Step 4 - Toxin B & A production leads to colon damage +/- pseudomembrane
11 CDI Pathogenesis Colonized no symptoms Antimicrobials C Diff exposure & acquisition Admitted to healthcare facility Infected Symptomatic
12 CDI: Host risk factors Advanced age Incidence higher among females, whites, and persons > 65 years 1 Death more common in persons > 65 years (5x greater risk) 2 Underlying illness and medical history 79% of 7421 patients with CDI had a comorbid condition 2 38% of 585 patients with NAP1 strain had ED visit in previous 12 weeks 2 Tube feeds 3 Immunosuppression Inflammatory bowel disease 2 Immune-suppressive treatment 2 Hematological malignancy/stem cell transplant (15-25x greater risk) 4 1. Lessa et al. N Engl J Med 2015; 372(9): See et al. Clin Infect Dis 2014; 58(10): Bliss et al. Ann Intern Med 1998; 129: Kombuj et al. Infect Control Hosp Epidemiol 2016; 37:8-15.
13 1. Pepin. Clin Infect Dis 2005; 2. Hensgens. J Antimicrob Chemother 2012; 3. Weber. Infect Control Hosp Epidemiol 2011; 4. Dubberke. Am J Infect Control Shaugnessy. Infect Control Hosp Epidemiol 2011; 6. Linney. Can J Hosp Pharm 2010; 7. Buendgens. J Crit Care 2014; 8. Dubberke. Infect Control Hosp Epidemiol CDI: Modifiable risk factors Exposure to antibiotics High Risk: Fluoroquinolones 1 3 rd and 4 th generation cephalosporins, clindamycin, carbapenems 2 Exposure to C. difficile spores Spores can remain viable for months 3 Contamination is increased in rooms of patients with active CDI 4,5 Hands of patients and personnel are easily contaminated 5 Gastric acid suppression Data, though inconsistent, implicate proton pump inhibitor (PPI) use 1,4,6,7 More study is needed to link restriction of PPI use with decreased CDI incidence 8
14 Clinical manifestations Illness caused by toxin-producing strains of C. difficile ranges from Asymptomatic carriers = Colonized Mild or moderate diarrhea Pseudo membranous colitis that can be fatal A median time between exposure to onset of CDI symptoms is of 2 3 days Risk of developing CDI after exposure ranges between 5-10 days to 10 weeks
15 CDI: Symptoms Watery diarrhea ( > 3 unformed stools in 24 or fewer consecutive hours) Loss of appetite Fever Nausea Abdominal pain and cramping
16 Epidemiology: Epidemic Strain BI/NAP1/027, toxinotype III First emerged in 2000 (Eastern Canada) 1 Associated with healthcare 2 More resistant to fluoroquinolones 3 Greater virulence Associated with more severe disease and mortality 4 Increased toxin A and B production 4,5 Polymorphisms in binding domain of toxin B 5 Oregon: 16% (11 of 68) strains with PFGE performed 1. McDonald et al. N Engl J Med 2005; 353(23): See et al. Clin Infect Dis 2014; 58(10): Stabler et al. J Med Micro 2008; 57(6): Warny et al. Lancet 2005; 366(9491):
17 Diagnostic testing
18 Best Strategy for C. difficile Testing Testing should be performed only on diarrheal stool Testing asymptomatic patients is not indicated Testing for cure is not recommended 2. Dubberke et al. Infect Control Hosp Epidemiol 2014; 35 (6):
19 Diagnostic tests for toxigenic C. difficile Tests by Type & Method Target(s) Characteristics Gold standards Toxigenic culture Cell cytotoxic assay Toxigenic C. difficile Toxins A or B Reference standard Difficult to perform Time consuming (24-48 h) Reference standard Highly sensitive for toxin vs. EIA Difficult to perform Time consuming (24-48 h) EIA Glutamate dehydrogenase Rapid diagnostic tests EIA NAAT RT-PCR Toxins A or B tcdb or tcdc genes LAMP tcda or tcdb genes References
20 Diagnostic tests for toxigenic C. difficile Tests by Type & Method Target(s) Characteristics Gold standards Toxigenic culture Cell cytotoxic assay EIA Toxigenic C. difficile Toxins A or B Glutamate dehydrogenase Must be paired with a test of toxin Variable sensitivity & specificity EIA Toxins A or B Variable sensitivity & specificity Rapid diagnostic tests NAAT RT-PCR tcdb or tcdc genes More expensive than EIA Highly sensitive & specific for toxigenic C. difficile May increase detection of colonization tcda-negative/tcdb-positive strains can cause disease LAMP tcda or tcdb genes tcda-positive/tcdb-negative strains not well described in human disease Caution required in interpreting negative results based on tcda testing alone by LAMP References
21 Guidance from the American Society for Microbiology Toxin A/B enzyme immunoassays have low sensitivity and should not be used as stand alone tests. 1 Highly sensitive screening tests like glutamate dehydrogenase antigen assays (GDH) should have positive results confirmed. Nucleic acid amplification that detects C. difficile toxin genes may be used as a stand alone test. 1. Am Soc Microbiol, 2010.
22 Sample multistep algorithm for rapid diagnosis of C. difficile infection JAMA. 2015;313(4): doi: /jama
23 Studies examining performance characteristics of multistep algorithms for rapid diagnosis of C. difficile infection NAAT-containing algorithms perform better Bagdasarian JAMA. 2015;313(4) doi: /jama
24 Treatment
25 Treatment options for CDI Smits Nat Rev Dis Primers Apr 7; 2: doi: /nrdp
26 Fecal microbiota transplant
27 Prevention
28 Overview Basic practices are prevention measures that should be in place at all times. Facilities should consider adopting some or all of the special approaches whenever ongoing opportunities for improvement are identified or as indicated by risk assessment. Basic Practices Special Approaches Appropriate use of antimicrobials Antimicrobial stewardship program Hand hygiene per CDC/WHO recommendations Measure healthcare personnel adherence Hand hygiene with soap and water after glove removal following care of CDI patients Intensify measurement of adherence Contact Precautions for CDI patients Measure healthcare personnel adherence Presumptive Contact Precautions while laboratory results are pending Prolonged duration of Contact Precautions Intensify measurement of adherence Cleaning and disinfection of equipment and environment Use of EPA-approved sporicidal disinfectant Assess adequacy of room cleaning Laboratory-based alert system for immediate notification to IP and clinical personnel of newly diagnosed CDI patients CDI surveillance, analysis, and reporting Educate healthcare personnel, patients, and families Dubberke et al. Infect Control Hosp Epidemiol 2014; 35(6):
29 Antimicrobial Stewardship Exposure to any antimicrobial is the single most important risk factor for C. difficile infection (CDI). Antibiotic exposure has lasting impact on the microbiome. Risk of CDI is elevated (7-10 fold) during and in the 3 months following antimicrobial therapy 1, % of CDI occurs within 30 days of antimicrobial exposure 1 Target high risk antibiotics for CDI prevention Fluoroquinolones 3 3rd/4th generation cephalosporins, carbapenems 2 1. Chang et al. Infect Control Hosp Epidemiol 2007; 28(8): Hsu et al. Am J Gastroenterol 2010; 105(11):
30 Currently 39% (1,642/4,184) of U.S. hospitals have an antibiotic stewardship program with all 7 core elements. The national goal is 100% of hospitals by
31 Seven Core Elements of Antimicrobial Stewardship 1. Leadership Commitment Dedicating necessary human, financial, technological resources 2. Accountability Appointing a single leader (physician or pharmacist) responsible for program outcomes 3. Drug Expertise A single dedicated pharmacist with responsibility to improve antibiotic use 4. Tracking Monitoring antibiotic prescribing and resistance patterns 5. Reporting Feedback of information on antibiotic use and resistance to frontline providers 6. Education Ongoing education of clinicians about resistance and optimal prescribing 7. Action Implementing at least one recommended action
32 Stewardship Approach: Feedback Non-restrictive feedback resulted in statistically significant reductions in incident CDI. Reductions in CDI attained through antimicrobial stewardship surpassed those attained through infection control measures. Tertiary Hospital in Quebec, Valiquette et al. Clin Infect Dis 2007; 45:S
33 Stewardship Approach: Restriction Restricting the use of ceftriaxone was associated with reduced rates of CDI. Formal restriction implemented Fig. 1 Hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile and extended-spectrum β-lactamase (ESBL)-producing coliform rates following a restrictive antibiotic policy in a district general hospital over 2 years. pt/occ.bds, patient-occupied bed-days; DDDs, defined daily doses. Dancer et al. Intl J Antimicrob Agents 2013; 41(2): District general hospital; Glasgow, UK,
34 A practical approach to CDI prevention
35 Targeted Assessment for Prevention (TAP) Strategy Target facilities/units Assess gaps in infection prevention in targeted areas Prevent infections by implementing interventions to address the gaps CDI TAP reports available in NHSN Work ongoing to use CO-CDI and other data sources to identify CDI cases from nursing homes and other community sources
36 CDI Risk Assessment Conduct a risk assessment annually and whenever CDI goals are not met 1 Use CDC s Targeted Assessment for Prevention (TAP) Strategy Pairing the results of a CDI facility assessment with the CDI Implementation Tool allows facilities to implement infection prevention strategies that most directly meet their needs. Dubberke et al. Infect Control Hosp Epidemiol 2014; 35(6):
37 CDI Case Review Review each CDI case (e.g., root cause analysis) Examine temporal and spatial relationships between cases to determine units at risk for transmission due to community-onset or hospital-onset CDI cases. The CDI Implementation Tool includes a template for CDI Case Review Dubberke et al. Infect Control Hosp Epidemiol 2014; 35(6):
38 A Coordinated Response A coordinated response is more effective than independent efforts 1 Partners in Prevention: The state and local health department and other state partners can assist and provide opportunities to extend efforts across the continuum of care Figure from CDC Vitals Signs: 1. Slayton et al. MMWR 2015; 64(30):
39 Communication During Patient Transfer of Multidrug-Resistant Organisms (MDROs) Effective Jan 2014, OAR requires facilities to notify in writing receiving institution that patient is infected or colonized with MDRO requiring transmission-based precaution in addition to standard precautions Examples: CRE, MRSA, C. diff Typically require additional precautions such as wearing mask, gown and gloves with patient contact, in some cases, patient isolation
40 Template form
41 IFT rule implementation OR hospitals and SNFs surveyed in 2015 & 2016 # of facilities surveyed:
42 IFT rule implementation We notify receiving facilities of MDROs at discharge Transferring facilities notify us of MDROs
43 What is your facility doing? 48
Clostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More information6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations
CLOSTRIDIUM DIFFICILE PREVENTION Beth Goodall, RN, BSN Board Certified in Infection Prevention and Control DCH Health System Epidemiology Director Welcome! Teaming Up to Prevent Infections! CLOSTRIDIUM
More information2018 UPDATE. INFECTION PREVENTION and CONTROL ISOLATION PRECAUTIONS & BLOODBORNE PATHOGENS
2018 UPDATE INFECTION PREVENTION and CONTROL ISOLATION PRECAUTIONS & BLOODBORNE PATHOGENS Catherine D. Bacheller, M.D. Medical Director, KMC & GVMC Infection Prevention and Control Assistant Professor
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More information2019 UPDATE 1/9/ ISOLATION PRECAUTIONS & BLOODBORNE PATHOGENS. Healthcare-Associated Infections (HAIs) INFECTION PREVENTION and CONTROL
DC* DC* 219 UPDATE INFECTION PREVENTION and CONTROL Healthcare-Associated Infections (HAIs) ISOLATION PRECAUTIONS & BLOODBORNE PATHOGENS Catherine D. Bacheller, M.D. Medical Director, KMC & GVMC Infection
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationActivity C: ELC Prevention Collaboratives
Clostridium difficile il (CDI) Infections Toolkit Activity C: ELC Prevention Collaboratives Carolyn Gould, MD MSCR Cliff McDonald, MD, FACP Division of Healthcare Quality Promotion Centers for Disease
More informationObjectives Clostridium difficile Infections, So Many Tests, Which One to Choose?
Objectives Clostridium difficile Infections, So Many Tests, Which One to Choose? March 9, 0 http://www.slh.wisc.edu/outreach-data/event-detail.php?id=03 Raymond P. Podzorski, Ph.D., D(ABMM) Clinical Microbiologist
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationClostridium difficile Essential information
Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationC. difficile: The Changing Epidemiology Evaluations Clostridium difficile Thank You to our Sponsors
C. difficile: The Changing Epidemiology Ghinwa Dumyati, MD University of Rochester Monroe County Department of Public Health Thank You to our Sponsors Evaluations School of Public Health, University at
More informationC Difficile - The Ultimate Challenge: Controlling the Spread
C Difficile - The Ultimate Challenge: Controlling the Spread Linda R. Greene, RN, MPS, CIC Manager of Infection Prevention Highland Hospital Rochester, NY University of Rochester Medical Center linda_greene@urmc.rochester.edu
More informationThe incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.
C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin
More informationClostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)
Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More information3/23/2012. Impact of Laboratory Testing on Detection and Treatment of Healthcare Associated Infection: The Case of CDI
Impact of Laboratory Testing on Detection and Treatment of Healthcare Associated Infection: The Case of CDI L. Clifford McDonald, MD Lance R. Peterson, MD March 27, 2012 1 Potential COI L. Clifford McDonald,
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationClostridium difficile infection surveillance: Applying the case definition
Clostridium difficile infection surveillance: Applying the case definition PICNet Conference March 3 rd 2016 Presented by: Tara Leigh Donovan, MSc Managing Consultant (Former Epidemiologist) 1 Disclaimer
More informationAn APIC Guide 2008 Guide to the Elimination of Clostridium difficile in Healthcare Settings
An APIC Guide 2008 Guide to the Elimination of Clostridium difficile in Healthcare Settings About APIC APIC s mission is to improve health and patient safety by reducing risks of infection and other adverse
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationL. Clifford McDonald, MD. Senior Advisor for Science and Integrity September 16, 2015
Controversies and Current Issues in Diagnosis, Surveillance, and Treatment of Clostridium difficile infeciton L. Clifford McDonald, MD Senior Advisor for Science and Integrity September 16, 2015 Division
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationClostridium difficile Diagnostic and Clinical Challenges
Papers in Press. Published December 11, 2015 as doi:10.1373/clinchem.2015.243717 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.243717 Clinical Chemistry 62:2 000 000
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More informationDUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015
DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News Volume 3, Number 6, June 2015 Diagnostic Testing for Clostridium difficile Infection Background Clostridium difficile
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationLe infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo
Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Istituto Nazionale per le Malattie Infettive «lazzaro Spallanzani», IRCCS-Roma The infectious cycle of transmission
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationC. Difficile Testing Protocol
C. Difficile Testing Protocol Caroline Donovan, RN, BSN, ONC- Infection Control Practitioner Abegail Pangan, RN, MSN, CIC- Infection Control Practitioner U.S. NEWS & WORLD REPORT 2017 2018 RANKINGS Acute
More informationTITLE OF PRESENTATION
TITLE OF PRESENTATION Can C. Subtitle difficile of Infection Presentation Rates Be Used to Judge Prevention Success for Hospitals? David P. Calfee, MD, MS Associate Professor of Medicine and Public Health
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.15 Rapid Diagnosis of Toxigenic Clostridium
More informationMolecular epidemiology of Clostridium difficile infection in British Columbia, Canada
Molecular epidemiology of Clostridium difficile infection in British Columbia, Canada Agatha Jassem, PhD Senior Scientist, BCCDC Public Health Laboratory Objectives Molecular typing methods for C. difficile
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationSherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine
Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine Chief Scientific Officer, Optimer Pharmaceuticals, Inc. Conflicts: Chief Scientific Officer,
More informationWhat s the diff with C. diff.? Accelerating Prevention Using a Bundle Approach
What s the diff with C. diff.? Accelerating Prevention Using a Bundle Approach GHA Learning & Action Network - 01/13/16 Russ Olmsted Dir., Infection Prevention & Control (IPC) System Office, Livonia olmstedr@trinity-health.org
More informationUnderstanding C. diff. atomalliance.org/cdifftraining
Understanding C. diff atomalliance.org/cdifftraining This booklet is a printed guide of the online educational resource atomalliance.org/cdifftraining Target Audience Understanding C. diff This educational
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationEPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)
EPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics & Epidemiology Associate Chief Medical Offer, UNC Health Care Medical
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More information! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery
Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal
More informationClostridioides difficile Infection: What s the BIG Stink?
Clostridioides difficile Infection: What s the BIG Stink? GLORIA MATHIS, RN, BSN, CIC 29 TH ANNUAL MEDICAL SURGICAL CONFERENCE APRIL 4, 2019 SAN FRANCISCO, CA I am sre my patient has C. diff. I cold smell
More informationClostridium difficile Infection in the Department of Defense (DOD):
1 1 Clostridium difficile Infection in the Department of Defense (DOD): 2007-2013 NMCPHC-EDC- TR-271-2015 By Charlotte Neumann and Uzo Chukwuma February 2015 Approved for public release. Distribution is
More informationHEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile
OBJECTIVES HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile Identify and describe the pathophysiology of C. diff. Identify and describe current therapies in treatment of C. diff Identify
More informationDETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:
More informationGetting to Know You. Tackling Clostridium difficile in Nursing Homes. Outline. C. difficile Epidemiology 11/18/2013
Tackling Clostridium difficile in Nursing Homes Getting to Know You Emily Lutterloh, MD, MPH Director, Bureau of Healthcare Associated Infections New York State Department of Health Outline Getting to
More informationRound Robin Highlights of Infection Control Practices
Round Robin Highlights of Infection Control Practices Arkansas Department of Health Healthcare-Associated Infections Program Staff To Isolate or Not To Isolate: That Is The Question Kelley Garner, MPH,
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationClostridium difficile
Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence
More informationC. DIFF QUIK CHEK COMPLETE. Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE NEXT PAGE
C. DIFF QUIK CHEK COMPLETE Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE PAGE CLINICIAN Would actionable C. difficile test results in less than 30 minutes improve patient
More informationFecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection
Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationECHO-Antibiotic Stewardship Program
ECHO-Antibiotic Stewardship Program More Interesting Recent Literature Updates April 20, 2017 Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Antibiotic
More informationESCMID Online Lecture Library. by author
ECDIS-NET: Update on Clostridium difficile epidemiology in Europe 1 E d J. K u i j p e r, S o f i e v a n D o r p a n d D a a n N o t e r m a n s. D e p a r t m e n t o f M e d i c a l M i c r o b i o
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationThe epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community. J Scott Weese DVM DVSc DipACVIM
The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community J Scott Weese DVM DVSc DipACVIM C. difficile Gram positive anaerobic sporeforming bacterium first
More informationC. DIFFICILE UPDATE. Heather Bell, DO Infectious Diseases Physician
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Questions Testing recommendations Treatment recommendations
More informationClinical Infectious Diseases IDSA GUIDELINE
Clinical Infectious Diseases IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and
More informationPreventing & Controlling the Spread of Infection
Preventing & Controlling the Spread of Infection Contributors: Alice Pong M.D., Hospital Epidemiologist Chris Abe, R.N., Senior Director Ancillary and Support Services Objectives Review the magnitude of
More informationPatient Safety Summit 2014
Patient Safety Summit 2014 The War on C Diff Mark Mellow, MD + C Diff The Organism Gram + bacillus Anaerobic Spore forming Intestinal flora (up to 35% hospitalized patients, 3% of healthy adults) Leading
More informationClostridium difficile Asymptomatic Carriers The Hidden Part of the Iceberg?
Clostridium difficile Asymptomatic Carriers The Hidden Part of the Iceberg? Disclosures Merck Canada, BD Diagnostics, AMD Medical, Canadian Institute for Health Research Merck Canada, Pfizer OBJECTIVES
More informationClostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures?
Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures? Clostridium difficile Clostridium difficile - first described in 1935 when it was isolated
More informationPrevention and Control of Healthcare-Associated Norovirus
Purpose: Audience: Policy: To prevent healthcare-associated norovirus infections in patients, employees, contract workers, volunteers, visitors and students and to control and eradicate norovirus infections
More informationIncidence of and risk factors for communityassociated Clostridium difficile infection
University of Iowa Iowa Research Online Theses and Dissertations 2010 Incidence of and risk factors for communityassociated Clostridium difficile infection Jennifer Lee Kuntz University of Iowa Copyright
More information7/30/2018 C. DIFFICILE UPDATE DISCLOSURE OUTLINE. Heather Bell, DO Infectious Diseases Physician. None to report
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Testing recommendations Treatment recommendations Isolation
More informationInfection Prevention & Control Core Skills Level 2
Infection Prevention & Control Core Skills Level 2 Learning outcomes Risk assessment of patients Critical examination of the situation MRSA, CDT & CPE Ongoing challenges future-proofing infection control
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationInfection control in Aged Residential Care Facilities. Dr Sally Roberts Clinical Advisor for IP&C Service, ADHB
Infection control in Aged Residential Care Facilities Dr Sally Roberts Clinical Advisor for IP&C Service, ADHB Background Endemic infections Epidemic infections Managing outbreaks Administrative measures
More informationIs C. difficile a Foodborne Disease?
Is C. difficile a Foodborne Disease? Brandi Limbago, Ph.D. Deputy Chief Clinical and Environmental Microbiology Branch IAFP 24 July 2012 Disclaimer: The findings and conclusions in this presentation are
More informationAnnex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening
Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention
More informationDiseases Update, C-Diff and Antibiotic Resistance
Diseases Update, C-Diff and Antibiotic Resistance L. Clifford McDonald, MD, FACP, SHEA Senior Advisor for Science and Integrity OSAP 2015 Dr. John Zapp Memorial Lecture: May 29, 2015 National Center for
More informationD DAVID PUBLISHING. Double Problem Clostridium difficile and Diabetes. 1. Introduction. Ioana Florina Iordan 1 and Carmen Manciuc 1, 2
Journal of Pharmacy and Pharmacology 6 (2018) 170-174 doi: 10.17265/2328-2150/2018.02.010 D DAVID PUBLISHING Ioana Florina Iordan 1 and Carmen Manciuc 1, 2 1. Sf. Paracheva Infectious Diseases Hospital,
More informationEach copy of any part of a JSTOR transmission must contain the same copyright notice that appears on the screen or printed page of such transmission.
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
More informationGUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics
More informationRapid-VIDITEST C. difficile Ag (GDH) Card/Blister
Li StarFish S.r.l. Via Cavour, 35-20063 Cernusco S/N (MI), Italy Tel. +39-02-92150794 - Fax. +39-02-92157285 info@listarfish.it -www.listarfish.it Rapid-VIDITEST C. difficile Ag (GDH) Card/Blister One
More informationNew Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility
New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility Gerald A. Capraro, Ph.D., D(ABMM) Director, Clinical Microbiology Carolinas Pathology Group Atrium
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationComparison of Clinical Features Between Inpatient and Outpatient Cases of Clostridium difficile Infection
Comparison of Clinical Features Between Inpatient and Outpatient Cases of Clostridium difficile Infection Marcus J. Belger A thesis submitted in partial fulfillment of the requirements for the degree of
More informationHistorical Perspective
The Diagnosis of C. difficile Infections: Does Molecular Make it More or Less difficile? Stephen M. Brecher Ph.D. VA Boston Health Care System BU School of Medicine The opinions expressed in this presentation
More informationPros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection
Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection Christopher R. Polage, MD, MAS Associate Professor of Pathology and Infectious Diseases UC Davis Disclosures Test materials
More informationEnteric Illness. Shigellosis
Section 3 Page 1 of 7 Notification Timeline: From Lab/Practitioner to Public Health: Immediately. From Public Health to Saskatchewan Health: Within 72 hours. Public Health Follow-up Timeline: Initiate
More informationINFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY MAY 2010, VOL. 31, NO. 5
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY MAY 2010, VOL. 31, NO. 5 SHEA-IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare
More informationAnnual Surveillance Summary: Clostridium difficile Infections in the Military Health System (MHS), 2016
Annual Surveillance Summary: Clostridium difficile Infections in the Military Health System (MHS), 2016 Charlotte Neumann and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views
More informationOriginal Article. Infection Control & Hospital Epidemiology (2019), 1 5 doi: /ice
Infection Control & Hospital Epidemiology (2019), 1 5 doi:10.1017/ice.2018.347 Original Article Healthcare provider diagnostic testing practices for identification of Clostridioides (Clostridium) difficile
More informationNorovirus Outbreak in a Children s Hospital. Jennifer Adams, MT, MPH, CIC April 23, 2015
Norovirus Outbreak in a Children s Hospital Jennifer Adams, MT, MPH, CIC April 23, 2015 Objectives Discuss the epidemiology, symptoms, and transmission of norovirus. Identify key infection control activities
More informationHEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS
HEALTHCARE- ASSOCIATED CLOSTRIDIUM DIFFICILE INFECTIONS IN CANADIAN ACUTE- CARE HOSPITALS SURVEILLANCE REPORT JANUARY 1 st, 2007 TO DECEMBER 31 st, 2012 TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationClostridium difficile 027, A Southern Hemisphere Perspective Dr. David Hammer, Medlab South, New Zealand A Webber Training Teleclass
Clostridium difficile 027 A Southern Hemisphere Perspective THE PRESS 6 July 2006 Dr. David Hammer Microbiology Registrar Medlab South Canterbury, NZ Total Annual Cost of Nosocomial Infection USA US$ 7
More informationClostridium difficile infection in an endemic setting in the Netherlands
Eur J Clin Microbiol Infect Dis (2011) 30:587 593 DOI 10.1007/s10096-010-1127-4 ARTICLE Clostridium difficile infection in an endemic setting in the Netherlands M. P. M. Hensgens & A. Goorhuis & C. M.
More information